Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of alpha-asarone in preparation of medicine for treating cerebral arterial thrombosis

A technology for ischemic stroke and asarone, which is applied in the field of biomedicine and can solve the problems that the therapeutic effect of α-asarone has not been reported yet.

Pending Publication Date: 2022-03-04
SICHUAN UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, the therapeutic effect of α-asarone on ischemic stroke has not been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of alpha-asarone in preparation of medicine for treating cerebral arterial thrombosis
  • Application of alpha-asarone in preparation of medicine for treating cerebral arterial thrombosis
  • Application of alpha-asarone in preparation of medicine for treating cerebral arterial thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Preparation of α-asarone injection emulsion

[0025] Weigh 0.50~50.0g of α-asarone and 50.0~200.0g of soybean oil for injection, put them in a suitable container, heat to 60~80°C under the protection of nitrogen gas, stir to dissolve; continue to weigh 6.0 g of egg yolk lecithin ~18.0g, add it, stir to dissolve (if necessary, add 0.10~0.50g of oleic acid, sodium oleate or a mixture of the two), and obtain the oil phase, set aside. Separately weigh 0~3.0g of Pluronic F-68, 0~25.0g of glycerol, measure about 800mL of water, heat to 60~80°C under the protection of nitrogen gas, stir to dissolve; the aqueous phase is obtained. Add the above oil phase to the water phase, shear at high speed for 5-15 minutes, add water to 1000mL, and prepare colostrum. Continue to homogenize the colostrum with a high-pressure homogenizer for 3 to 6 times, so that the average particle size of the milk droplets after homogenization is not greater than 0.5 μm, filter through a filter ...

Embodiment 2

[0026] Example 2 Preparation of α-asarone injection emulsion

[0027]Weigh 10.0 g of α-asarone, 50.0 g of soybean oil for injection, and 50.0 g of medium-chain triglyceride (MCT) for injection, put them in a suitable container, heat to 60-80°C under nitrogen protection, and stir to make Dissolving; continue to weigh 12.0 g of egg yolk lecithin and 0.3 g of sodium oleate, add them, stir to dissolve, and obtain an oil phase, which is set aside. Separately weigh 22.0g of glycerin, measure about 800mL of water, heat to 60~80°C under the protection of nitrogen gas, and stir to dissolve; the aqueous phase is obtained. Add the above oil phase to the water phase, shear at high speed for 5-15 minutes, add water to 1000mL, and prepare colostrum. Continue to homogenize the colostrum with a high-pressure homogenizer for 3 to 6 times, so that the average particle size of the milk droplets after homogenization is not greater than 0.5 μm, filter the membrane, and fill the filtrate into 5mL ...

Embodiment 3

[0028] Example 3 Preparation of α-asarone injection emulsion

[0029] Weigh 20.0 g of α-asarone, 100.0 g of soybean oil for injection, and 100.0 g of medium-chain triglyceride (MCT) for injection, put them in a suitable container, heat to 60-80°C under nitrogen protection, and stir to make Dissolving; continue to weigh 12.0 g of egg yolk lecithin and 0.3 g of oleic acid, add it, stir to dissolve, and obtain an oil phase for later use. Separately weigh 22.0g of glycerin, measure about 800mL of water, heat to 60~80°C under the protection of nitrogen gas, and stir to dissolve; the aqueous phase is obtained. Add the above oil phase to the water phase, shear at high speed for 5-15 minutes, add water to 1000mL, and prepare colostrum. Continue to homogenize the colostrum with a high-pressure homogenizer for 3 to 6 times, so that the average particle size of the milk droplets after homogenization is not greater than 0.5 μm, filter the membrane, and fill the filtrate into 5mL or 10mL ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention relates to application of a medicine taking alpha-asarone as a unique pharmacological active component in treatment of cerebral arterial thrombosis. The medicine provided by the invention can be used for effectively treating cerebral arterial thrombosis and has no obvious toxic or side effect. The medicine can obviously increase the blood flow ratio of the infarct side half brain to the opposite side half brain of a middle cerebral artery occlusion ischemia reperfusion rat and reduce the cerebral infarction volume; the nerve function score is obviously improved, and the lifetime of the model rat is prolonged; the occurrence rate of epilepsy caused by cerebral arterial thrombosis is obviously reduced.

Description

technical field [0001] The present invention relates to a new application of α-asarone, in particular to the application of a drug with α-asarone as the only pharmacologically active ingredient in the treatment of ischemic stroke. The invention can be used for clinical treatment of ischemic stroke and belongs to the field of biomedicine. Background technique [0002] Stroke is the second leading cause of death worldwide and the leading cause of permanent disability, resulting in a huge social and economic burden. In China, the mortality rate of stroke is decreasing. However, the incidence rate shows an increasing trend, and there are nearly 2.4 million new cases each year. Stroke can be clinically divided into hemorrhagic stroke and ischemic stroke. Ischemic stroke is mainly caused by thrombus formation or embolus shedding due to atherosclerosis. When an ischemic stroke occurs, blood circulation in the brain is reduced or absent, which in turn leads to neuronal cell damag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/09A61P9/10
CPCA61K31/09A61P9/10
Inventor 毛声俊张坤冯欣倩刘琪张检张迪母珂蔓高小凤
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com